GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » MDxHealth SA (NAS:MDXH) » Definitions » Gross Margin %

MDxHealth (MDxHealth) Gross Margin % : 65.32% (As of Dec. 2023)


View and export this data going back to 2008. Start your Free Trial

What is MDxHealth Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. MDxHealth's Gross Profit for the three months ended in Dec. 2023 was $12.67 Mil. MDxHealth's Revenue for the three months ended in Dec. 2023 was $19.40 Mil. Therefore, MDxHealth's Gross Margin % for the quarter that ended in Dec. 2023 was 65.32%.


The historical rank and industry rank for MDxHealth's Gross Margin % or its related term are showing as below:

MDXH' s Gross Margin % Range Over the Past 10 Years
Min: 0.25   Med: 55.48   Max: 74.81
Current: 62.58


During the past 13 years, the highest Gross Margin % of MDxHealth was 74.81%. The lowest was 0.25%. And the median was 55.48%.

MDXH's Gross Margin % is ranked better than
68.52% of 216 companies
in the Medical Diagnostics & Research industry
Industry Median: 45.595 vs MDXH: 62.58

MDxHealth had a gross margin of 65.32% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for MDxHealth was 59.70% per year.


MDxHealth Gross Margin % Historical Data

The historical data trend for MDxHealth's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MDxHealth Gross Margin % Chart

MDxHealth Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.25 43.58 47.50 51.87 62.58

MDxHealth Quarterly Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 56.04 59.29 59.66 64.87 65.32

Competitive Comparison of MDxHealth's Gross Margin %

For the Diagnostics & Research subindustry, MDxHealth's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MDxHealth's Gross Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, MDxHealth's Gross Margin % distribution charts can be found below:

* The bar in red indicates where MDxHealth's Gross Margin % falls into.



MDxHealth Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

MDxHealth's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=43.9 / 70.193
=(Revenue - Cost of Goods Sold) / Revenue
=(70.193 - 26.264) / 70.193
=62.58 %

MDxHealth's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=12.7 / 19.398
=(Revenue - Cost of Goods Sold) / Revenue
=(19.398 - 6.727) / 19.398
=65.32 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


MDxHealth  (NAS:MDXH) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

MDxHealth had a gross margin of 65.32% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


MDxHealth Gross Margin % Related Terms

Thank you for viewing the detailed overview of MDxHealth's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


MDxHealth (MDxHealth) Business Description

Traded in Other Exchanges
N/A
Address
Rue d’Abhooz, 31, Cap Business Center, Herstal, Liege, BEL, 4040
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.